BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 20572292)

  • 21. Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells.
    Okamoto S; Ito K; Sasano H; Moriya T; Niikura H; Terada Y; Sato S; Okamura K; Yaegashi N
    Tohoku J Exp Med; 2005 May; 206(1):31-40. PubMed ID: 15802873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
    Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
    Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
    Saleh HA; El-Fakharany M; Makki H; Kadhim A; Masood S
    Diagn Cytopathol; 2009 May; 37(5):324-32. PubMed ID: 19191294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases.
    Fujiwara M; Taube J; Sharma M; McCalmont TH; Kim J
    J Cutan Pathol; 2010 Sep; 37(9):938-43. PubMed ID: 20492080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions.
    Wiseman W; Michael CW; Roh MH
    Diagn Cytopathol; 2011 Sep; 39(9):651-6. PubMed ID: 20949455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens.
    Ren S; Klump W
    Arch Pathol Lab Med; 2019 Jun; 143(6):677-682. PubMed ID: 29688031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tubal origin of 'ovarian' low-grade serous carcinoma.
    Li J; Abushahin N; Pang S; Xiang L; Chambers SK; Fadare O; Kong B; Zheng W
    Mod Pathol; 2011 Nov; 24(11):1488-99. PubMed ID: 21701538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serous carcinoma of the ovary with squamous differentiation: a case report and a literature review.
    Roberts DE; Lombard CM
    Int J Gynecol Pathol; 2013 Sep; 32(5):459-63. PubMed ID: 23896710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
    Chapel DB; Husain AN; Krausz T; McGregor SM
    Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
    Ordóñez NG
    Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry.
    Alberti N; Serrano-Egea A; García-García E; Ballestín C; Pérez-Barrios A; López-Ríos F; de Agustín P
    Acta Cytol; 2007; 51(2):203-6. PubMed ID: 17425204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
    Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
    Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
    Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
    Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAX8 is expressed in anaplastic thyroid carcinoma diagnosed by fine-needle aspiration: a study of three cases with histological correlates.
    Bellevicine C; Iaccarino A; Malapelle U; Sasso FC; Biondi B; Troncone G
    Eur J Endocrinol; 2013 Sep; 169(3):307-11. PubMed ID: 23811186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pax8 as a useful adjunct marker to differentiate pancreatic serous cystadenoma from clear cell renal cell carcinoma in both cytologic and surgical specimens.
    Chi Z; Xu J; Karamchandani DM; Peng L
    Diagn Pathol; 2023 Apr; 18(1):54. PubMed ID: 37098593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
    Boyd C; McCluggage WG
    Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
    Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
    Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
    Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
    Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.